8
Participants
Start Date
May 21, 2021
Primary Completion Date
November 17, 2022
Study Completion Date
November 17, 2022
Psilocybin and Midazolam
"The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.~The midazolam in this study will be administered intravenously. The total dose administered to a given subject is dependent on the individual's level of amnesia, sedation scale score, age, and weight."
UWHealth, 600 Highland Avenue, Madison
University of Wisconsin, Madison
OTHER